Abstract
Liver transplantation (LTx) is the treatment of choice for patients with end-stage liver disease (ESLD). Improvement in outcomes (allograft and patient survival) has led to widespread use of LTx worldwide. However, new problems that include severe organ shortage, recurrence of primary disease, opportunistic infections, and development of de novo malignancies are the major problems affecting further implementation of LTx.